Skip to content
Declared
Official portrait of Hildegarde Naughton
Photo: Houses of the Oireachtas

Politician · TD · 34th Dáil

Hildegarde Naughton

Fine Gael

Constituency / panel
Galway West
Membership
2024-11-29 → current
Office
Minister for Education and Youth (2025-11-18 → current)
Office
Minister of State at the Department of Children, Equality, Disability, Integration and Youth with responsibility for Disability (2025-01-23 → 2025-05-01)
Office
Minister of State at the Department of Children, Disability and Equality (2025-05-02 → 2025-11-18)

Lobbying returns

Returns filed on the Register of Lobbying, newest first, with the policy area and intended results as the lobbyist published them.

Download CSV 349 rows, with the filters applied
Register of Lobbying2016-05-20

Lobbying return by Samaritans Ireland

Health
Intended results

We wanted to generate support for our manifesto asks and a public commitment from candiidates to support them if elected.

Derived link · Matched by exact company name

Published name "Samaritans Ireland" equals CRO name "SAMARITANS IRELAND" (CRO 450409) after normalising legal forms such as Ltd = Limited. No other CRO company has this name. Names can be shared, so compare the address and dates on the CRO record.

Register of Lobbying2016-01-22

Lobbying return by Sage Advocacy

Health
Intended results

To raise the issue of Chemical Restraint within the Assisted Decision Making (Capacity) legislation.

Derived link · Matched by name with added legal form

Published name "Sage Advocacy" has no legal form. "SAGE ADVOCACY COMPANY LIMITED BY GUARANTEE" (CRO 610824) is the only CRO company with that name plus any legal form (Limited, DAC, UC, CLG, PLC or Teoranta). Confirm against the CRO record before relying on it.

Register of Lobbying2016-01-21

Lobbying return by Muscular Dystrophy Society of Ireland GLC

Health
Intended results

Increased Personal Assistance Hours, Increase in the provision of accessible housing for people with disabilities, Access to novel and newly approved treatments, The Provision of A clinical Trial Site, The Preservation of MDI’s funding